Literature DB >> 9260575

Molecular cytogenetics of childhood acute myelogenous leukaemias.

T Leblanc1, R Berger.   

Abstract

Chromosome abnormalities of childhood acute myeloblastic leukaemia, observed at least in 70-80% of cases, are presently recognized as important parameters for diagnostic, prognostic and follow-up purposes. These abnormalities are numerical, structural or both numerical and structural. They are also classified in "primary" abnormalities, usually more or less related with one subtype of leukaemia, and "secondary" abnormalities thought to appear in a second time. Chromosome abnormalities of childhood acute myeloblastic leukaemia (AML) are not basically qualitatively different from those of adult AML. The main difference lies in the incidence of the various types of abnormalities, and these differences appear to be more marked for age extremes such as infants and elderly patients. In total, 3 common abnormalities are more frequently observed in childhood than in adult AML; t(8;21) in AML-M2, monosomy 7 in AML-M4, der(11q) in AML-M5. In addition, molecular rearrangements associated with chromosomal abnormalities are dependent on the type of rearrangement and not on age. As in adult AML, the prognostic value of chromosome abnormalities has been diversely evaluated; some anomalies seem to be related to a shorter survival than others independent of the various therapeutic protocols used. In the present work, chromosome abnormalities of childhood AML have been reviewed according to cytologic subtypes as well as to some clinical settings. Special attention has been paid to abnormalities frequently or exclusively encountered in children.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9260575     DOI: 10.1111/j.1600-0609.1997.tb00953.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  2 in total

1.  Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo.

Authors:  Guang-Biao Zhou; Hui Kang; Lan Wang; Li Gao; Ping Liu; Jun Xie; Feng-Xiang Zhang; Xiang-Qin Weng; Zhi-Xiang Shen; Jue Chen; Long-Jun Gu; Ming Yan; Dong-Er Zhang; Sai-Juan Chen; Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2006-12-29       Impact factor: 22.113

2.  Bilateral orbital myeloid sarcoma as initial manifestation of acute myeloid leukemia.

Authors:  Kamel Hmidi; Sonia Zaouali; Riadh Messaoud; Bahri Mahjoub; Wafa Ammari; Leila Bacha; Adnene Laatiri; Salah Jenzeri; Moncef Khairallah
Journal:  Int Ophthalmol       Date:  2007-05-24       Impact factor: 2.029

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.